ACE2 and cancer: These mechanisms certainly include not only host-related factors such as age or cachexia, cancer- or drug-induced hypercoagulability states, or the possible hyperexpression of entry factors such as angiotensin-converting enzyme 2 or neurophilin-1 [24], but also cancer-related myeloid cell dysfunction and T-cell exhaustion, both of which impair antiviral immunity [25].